Treats Moderate. ANDA 207261, held by Xiromed. Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 207261 (Estradiol And Norethindrone Acetate), held by Xiromed, was first approved by FDA on Feb 10, 2017, with 4 approved supplements and 0 published complete response letters.
Abigale and Abigale Lo are indicated for: Abigale and Abigale Lo are an estrogen and progestin combination indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitations of Use: When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. Prevention of Postmenopausal Osteoporosis Limitations of Use: When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 10, 2017 | Original application | Approved | None posted |
| Estradiol And Norethindrone Acetate0.5MG;0.1MG · tablet;oral | Estradiol; Norethindrone Acetate | Rx |
| Estradiol And Norethindrone Acetate1MG;0.5MG · tablet;oral | Estradiol; Norethindrone Acetate | Rx |
| Jun 20, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 20, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 20, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 20, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 10, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters